Pfizer

Pfizer's Reminder Recall Resources are Available

There may be gaps in immunization coverage for your patients that leave them at risk for certain vaccine-preventable diseases.  The ACIP, AAP, and AAFP recommend the use of reminder recall systems by vaccination providers to increase vaccination rates.  

Pfizer offers reminder recall resources that may help support your organization's efforts to increase vaccination and well visit adherence through personalized postcards that can assist in your vaccination outreach efforts.  These postcards are not brand-specific and are intended for your patients who may have missed or are due for CDC-recommended vaccines, or who may be due for a well visit.

 To learn more, click here and share your contact information via email to request a call from a Pfizer Vaccines representative to review Pfizer's reminder recall resources and the program enrollment process.  As a note, by providing your contact information, you are therefore affirming your consent to provide your contact information to a local Pfizer Vaccine Representative.  

Available July 1: the first over-the-counter test that offers fast and accurate testing for both COVID-19 and Flu A/B

Beginning July 1, 2024, the LUCIRA by Pfizer COVID-19 & Flu Test will be available to order for all PRN members. This cordless device gives you results in 30 minutes, showing a positive result in as few as 11 minutes.

LUCIRA by Pfizer COVID-19 and Flu A & B test offers the convenience of an in-office test with molecular testing and PCR-quality accuracy for ages 2 and up.

Swab, stir and detect. 3 simple steps with an easy-to-read display. Click on the image below for more details.

Available April 1: The only FDA-approved vaccine that helps prevent all 5 leading types of meningococcal meningitis

Source: www.penbraya.com

PENBRAYA is available for order beginning April 1, 2024.  PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y.  PENBRAYA is approved for use in individuals 10 through 25 years of age. 

PENBRAYA combines 2 vaccines that have nearly 10 years of experience to help protect against all 5 leading types of meningitis—A, B, C, W, and Y. Patients can now get the broadest protection against all 5 leading types of meningococcal meningitis with the fewest shots.

Click here for more information.

If you are interested in ordering, please contact Tina Clark, Contract Administrator, at tina@prn-gpo.com or (888)776-2360.

Pfizer COVID-19 Vaccine NDC Notification

Updated COVID-19 vaccines from BioNTech and Pfizer are available. Here is a brief update on the market landscape:

  • Pfizer has substantial supply of 2023-2024 Formula COVID-19 vaccines and does not have any shortages at this time. 

  • Following FDA approval and emergency use authorization, the CDC issued recommendations the week of September 11, 2023.

  • Pfizer has shipped and delivered several million doses of 2023-2024 Formula COVID-19 vaccines. We continue to fulfill orders and anticipate delivering millions of additional doses each week.

  • Pfizer is actively working with our Wholesaler and Distributors partners and customers to help ensure access by shipping product directly to customers when and where needed.

Regarding reimbursement, there may be confusion related to reimbursement for COVID-19 vaccines and out of pocket costs to patients.  Under Section 3203 of the CARES Act and subsequent U.S. government guidance, most commercial health plans (excluding ACA grandfathered plans), must cover updated ACIP-recommended COVID-19 vaccines and their administration with no patient cost-sharing immediately upon approval or authorization for emergency use. As a result, commercial health plans must cover and reimburse claims for the updated Pfizer-BioNTech COVID-10 vaccines (2023-24 formula) as of the date of FDA approval and emergency use authorization on September 11, 2023.

In July 2023, HHS issued guidance to payors to prepare to cover COVID-19 vaccination with the onset of the COVID-19 vaccine Commercialization. To review this letter click on the attached link Letter from HHS Secretary on COVID-19 Vaccine Coverage | HHS.gov

 Click here to request a call from a Pfizer Vaccines Representative for information about updated COVID-19 vaccines from BioNTech and Pfizer or contact Tina Clark, your local Pfizer Vaccines Representative.

Vaccinate Against RSV this Respiratory Season

There are options to help prevent RSV and its potential serious consequences on infants and older adults this respiratory season.  ABRYSVOTM (Respiratory Syncytial Virus Vaccine) from Pfizer is the only FDA-approved and ACIP-recommended RSV vaccine to help protect both older adults and infants (via maternal immunization) from RSV.

RSV can lead to serious outcomes in older adults (annual data)

  • 2.2 million symptomatic illnesses

  • 60,000-160,000 hospitalizations

  • 6000-10,000 deaths

RSV is the leading cause of hospitalization in infants aged <1 year

  • Hospitalization burden is greatest in infants under 6 months of age, peaking between 1 and 2 months of age 3

  • In severe cases, RSV may result in acute respiratory failure, hypoxia and carbon dioxide retention, apnea, and death

 

Please review the Indications and Important Safety Information for ABRYSVO™ below.

 

ABRYSVO™ is ACIP recommended

  • The CDC’s ACIP recommends ABRYSVO™ for adults 60 years and older based on shared clinical decision making.6 The recommendation was published in the July 21, 2023, issue of MMWR, and is available here.

  • The CDC's ACIP recommends ABRYSVO for pregnant people as a one-time dose at 32 weeks and zero days’ through 36 weeks and 6 days’ gestation using seasonal administration (meaning September–January in most of the continental United States) for prevention of RSV-associated LRTI in infants aged <6 months.  The recommendation was published in the October 6, 2023, issue of MMWR, and is available here.

 

ABRYSVO™ is ACOG recommended

  • The American College of Obstetricians and Gynecologists (ACOG) recommends a single dose of maternal RSV vaccination for pregnant individuals 32 through 36 weeks gestation*, using seasonal administration, to prevent RSV lower respiratory tract infection in infants.

 

* Beginning on the first day of the 32nd week through the last day of the 36th week